Ultragenyx Pharmaceutical | RARE - Ebitda


Ultragenyx Pharmaceutical reported $-155M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Immunic USD -22.78M 753K Jun/2024
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Kyowa Hakko Kirin JPY 53.91B 36.74B Jun/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Moderna USD -1.26B 468M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026